Welcome to Francis Academic Press

Academic Journal of Medicine & Health Sciences, 2023, 4(5); doi: 10.25236/AJMHS.2023.040507.

Theoretical Study on the Binding Properties of Inhibitors to Myeloid Cell Leukemia 1


Youxin Cui

Corresponding Author:
Youxin Cui

School of Physics and Electronics, Shandong Normal University, Jinan, China


Myeloid leukemia 1 (Mcl-1) is a key anti-apoptotic member of the Bcl-2 protein family, and its overexpression or upregulation has been found in numerous cancer cells, which not only leads to tumorigenesis mediated by apoptotic escape modality, but also causes resistance to multiple subsequent anti-cancer therapies. The development of small molecule inhibitors that specifically target Mcl-1 and restore the blocked apoptotic pathway in cancer cells has emerged as a realistic solution for oncology drug design. Therefore, an in-depth study of the mechanism of action of inhibitors with Mcl-1 is important for the design of efficient drugs targeting Mcl-1. In this study, using molecular dynamics (MD) simulations, correlation analysis and principal component analysis, we revealed that the binding of inhibitors significantly altered the kinetic behavior of Mcl-1 and led to a conformational rearrangement of Mcl-1. Subsequently, the molecular mechanics-generalized Born surface area (MM-GBSA) method was used to further explore the binding ability of different inhibitors to Mcl-1, and the results showed that the calculated binding free energies agreed well with the experimental values, and van der Waals interactions and electrostatic interactions provided the main favorable contribution in the binding of inhibitors to Mcl-1. Furthermore, the interaction analysis showed a large number of hydrophobic interactions and hydrogen bonding between the inhibitor and Mcl-1. Finally, the residues F228, M231, M250, V253, T266, L267 and F270 and R263 were identified by residue-based free energy decomposition calculations to provide important energetic contributions to the binding of the inhibitor to Mcl-1 and could be key targets for the design of Mcl-1 inhibitors.


Molecular dynamics simulation; Principal component analysis; Mcl-1; MM-GBSA; Cross correlation analysis

Cite This Paper

Youxin Cui. Theoretical Study on the Binding Properties of Inhibitors to Myeloid Cell Leukemia 1. Academic Journal of Medicine & Health Sciences (2023) Vol. 4, Issue 5: 37-48. https://doi.org/10.25236/AJMHS.2023.040507.


[1] Michael D. Jacobson, Miguel Weil, Martin C. Raff. Programmed Cell Death in Animal Development. Cell, 1997, 88(3): 347-354.

[2] Douglas Hanahan, Robert A. Weinberg. Hallmarks of Cancer: The Next Generation. Cell, 2011, 144(5): 646-674.

[3] Michael F., Tolkovsky A. M., Vilmante B., et al. Neuronal Cell Death. Physiological Reviews, 2018, 98(2): 813-880.

[4] V. V. Senichkin, A. Y. Streletskaia, B. Zhivotovsky and G. S. Kopeina, Molecular comprehension of Mcl-1: from gene structure to cancer therapy, Trends Cell Biol., 2019, 29, 549–562.

[5] P. E. Czabotar, G. Lessene, A. Strasser and J. M. Adams, Control of apoptosis by the BCL-2 protein family: implica-tions for physiology and therapy, Nat. Rev. Mol. Cell Biol., 2014, 15, 49–63.

[6] S. Shaw, Z. Bian, B. Zhao, J. C. Tarr, N. Veerasamy, K. O. Jeon, J. Belmar, A. L. Arnold, S. A. Fogarty, E. Perry and J. L. Sensintaffar, Optimization of potent and selective tricyclic indolediazepinone myeloid cell leukemia-1 inhibi-tors using structure-based design, J. Med. Chem., 2018, 61, 2410–2421.

[7] Youle R. J., Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nature Reviews Molecular Cell Biology, 2008, 9(1): 47-59.

[8] Elkholi R., Floros K. V., Chipuk J. E. The Role of BH3-Only Proteins in Tumor Cell Development, Signaling, and Treatment. Genes & Cancer, 2011, 2(5):523-537.

[9] Maji S, Panda S, Samal SK, et al. Bcl-2 antiapoptotic family proteins and chemoresistance in cancer. Adv Cancer Res, 2018, 137: 37-75

[10] Westphal D., Dewson G., Czabotar P. E., et al. Molecular biology of Bax and Bak activation and action. Biochimica et biophysica acta, 2011, 1813(4): 521-31.

[11] Llambi F., Wang Y. M., Victor B., et al. BOK Is a Non-canonical BCL-2 Family Effector of Apoptosis Regulated by ER-Associated Degradation. Cell, 2016:421-433.

[12] N. N. Danial and S. J. Korsmeyer, Cell death: critical control point, Cell, 2004, 116, 205–219.

[13] J. C. Reed, Bcl-2 and the regulation of programmed cell death, J. Cell Biol., 1994, 124, 1–6.

[14] N. F. Pelz, Z. Bian, B. Zhao, S. Shaw, J. C. Tarr, J. Belmar, C. Gregg, D. V. Camper, C. M. Goodwin, A. L. Arnold and J. L. Sensintaffar, Discovery of 2-indole-acylsulfonamide myeloid cell leukemia 1 (Mcl-1) inhibitors using fragment-based methods, J. Med. Chem., 2016, 59, 2054–2066.

[15] S. Cory and J. M. Adams, The Bcl-2 family: regulators of the cellular life-or-death switch, Nat. Rev. Cancer, 2002, 2, 647–656.

[16] M. Bruncko, L. Wang, G. S. Sheppard, D. C. Phillips, S. K. Tahir, J. Xue, S. Erickson, S. Fidanze, E. Fry, L. Hasvold and G. J. Jenkins, Structure-guided design of a series of Mcl-1 inhibitors with high affinity and selectivity, J. Med. Chem., 2015, 58, 2180–2194.

[17] J. P. Burke, Z. Bian, S. Shaw, B. Zhao, C. M. Goodwin, J. Belmar, C. F. Browning, D. Vigil, A. Friberg, D. V. Camper and O. W. Rossanese, Discovery of tricyclic indoles that potently inhibit Mcl-1 using fragment-based methods and structure-based design, J. Med. Chem., 2015, 58, 3794–3805.

[18] Q. Ding, X. He, W. Xia, J. M. Hsu, C. T. Chen, L. Y. Li, D. F. Lee, J. Y. Yang, X. Xie, J. C. Liu and M. C. Hung, Myeloid cell leukemia-1 inversely correlates with glycogen synthase kinase-3b activity and associates with poor prognosis in human breast cancer, Cancer Res., 2007, 67, 4564–4571.

[19] T. Zhang, C. Zhao, L. Luo, H. Zhao, J. Cheng and F. Xu, The expression of Mcl-1 in human cervical cancer and its clinical significance, Med. Oncol., 2012, 29, 1985–1991. 

[20] Beroukhim R, Mermel CH, Porter D, et al. The landscape of somatic copy-number alteration across human cancers. Nature. 2010; 463(7283): 899–905.

[21] Wei G, Margolin AA, Haery L, et al. Chemical genomics identifies small-molecule MCL-1 repressors and BCL-xL as a predictor of MCL-1 dependency. Cancer Cell. 2012; 21(4):547–562.

[22] Ding Q, He X, Xia W, et al. Myeloid cell leukemia-1 inversely cor-relates with glycogen synthase kinase-3beta activity and associates with poor prognosis in human breast cancer. Cancer Res. 2007; 67(10): 4564–4571.

[23] Song L, Coppola D, Livingston S, Cress D, Haura EB. Mcl-1 regulates survival and sensitivity to diverse apoptotic stimuli in human non-small cell lung cancer cells. Cancer Biol Ther. 2005; 4(3):267–276.

[24] Krajewska M, Krajewski S, Epstein JI, et al. Immunohistochemical analysis of bcl-2, bax, bcl-X, and Mcl-1 expression in prostate cancers. Am J Pathol. 1996; 148(5):1567–1576.

[25] Miyamoto Y, Hosotani R, Wada M, et al. Immunohistochemical analy-sis of Bcl-2, Bax, Bcl-X, and Mcl-1 expression in pancreatic cancers. Oncology. 1999;56(1):73–82.

[26] Brotin E, Meryet-Figuiere M, Simonin K, et al. Bcl-XL and MCL-1 constitute pertinent targets in ovarian carcinoma and their concomi-tant inhibition is sufficient to induce apoptosis. Int J Cancer. 2010; 126(4):885–895.

[27] Derenne S, Monia B, Dean NM, et al. Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. Blood. 2002; 100(1):194–199.

[28] I. E. Wertz, et al., Sensitivity to antitubulin chemotherapeu-tics is regulated by MCL-1 and FBW7, Nature, 2011, 471, 110–114.

[29] S. H. Wei, K. Dong, F. Lin, X. Wang, B. Li, J. J. Shen, Q. Zhang, R. Wang and H. Z. Zhang, Inducing apoptosis and enhancing chemosensitivity to gemcitabine via RNA interference targeting MCL-1 gene in pancreatic carcinoma cell, Cancer Chemother. Pharmacol, 2008, 62, 1055–1064.

[30] S. H. Kim, M. S. Ricci and W. S. El-Deiry, MCL-1: a gateway to TRAIL sensitization, Cancer Res., 2008, 68, 2062–2064.

[31] S. K. Tahir, X. Yang, M. G. Anderson, S. E. Morgan-Lappe, A. V. Sarthy, J. Chen, R. B. Warner, S. C. Ng, S. W. Fesik, S. W. Elmore, S. H. Rosenberg and C. Tse, Influence of BCL-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737, Cancer Res., 2007, 67, 1176–1183.

[32] Wei SH, Dong K, Lin F, et al. Inducing apoptosis and enhancing chemosensitivity to gemcitabine via RNA interference targeting Mcl-1 gene in pancreatic carcinoma cell. Cancer Chemother Pharmacol. 2008;62(6):1055–1064.

[33] Pawlowski J., Kraft A. S. Bax-induced apoptotic cell death. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97(2):529-529.

[34] Westphal D., Dewson G., Czabotar P. E., et al. Molecular biology of Bax and Bak activation and action. Biochimica et biophysica acta, 2011, 1813(4): 521-31.

[35] M. R. Arkin and J. A. Wells, Small-molecule inhibitors of protein-protein interactions: progressing towards the dream, Nat. Rev. Drug Discovery, 2004, 3, 301–317.

[36] Vogler M. BCL2 A1: The underdog in the BCL2 family. Cell Death Differ, 2012, 19(1): 67-74.

[37] Dror R. O., Dirks R. M., Grossman J. P., et al. Biomolecular Simulation: A Computational Microscope for Molecular Biology. Annual Review of Biophysics, 2012, 41: 429-452.

[38] Dušan P., Shina Caroline Lynn K. Molecular modeling of conformational dynamics and its role in enzyme evolution. Current Opinion in Structural Biology, 2018, 52: 50-57.

[39] J.M. Wang, P. Morin, W. Wang, and P.A. Kollman, Use of MM-PBSA in reproducing the binding free energies to HIV-1 RT of TIBO derivatives and predicting the binding mode to HIV-1 RT of efavirenz by docking and MM-PBSA, J. Am. Chem. Soc. 123 (2001), 5221–5230. 

[40] W. Wang and P.A. Kollman, Free energy calculations on dimer stability of the HIV protease using molecular dynamics and a continuum solvent model, J. Mol. Biol. 303 (2000), 567–582.

[41] David C. C., Jacobs D. J.: Principal Component Analysis: A Method for Determining the Essential Dynamics of Proteins. Methods Mol Biol 2014, 1084:193-226.

[42] Chen J., Wang L., Wang W., Sun H., Pang L., Bao H.: Conformational transformation of switch domains in GDP/K-Ras induced by G13 mutants: An investigation through Gaussian accelerated molecular dynamics simulations and principal component analysis. Comput Biol Med 2021, 135:104639.

[43] Arnold G. E., Ornstein R. L.: Molecular dynamics study of time-correlated protein domain motions and molecular flexibility: cytochrome P450BM-3. Biophysical Journal 1997, 73:1147-1159.

[44] Fataftah H., Karain W.: Detecting protein atom correlations using correlation of probability of recurrence. Proteins: Structure, Function, and Bioinformatics 2014, 82:2180-2189.

[45] Jakalian A., Bush B. L., Jack D. B., Bayly C. I. Fast, efficient generation of high-quality atomic charges. AM1-BCC model: I. Method. Journal of Computational Chemistry, 2000, 21(2): 132-146.

[46] Jakalian A., Jack D. B., Bayly C. I. Fast, efficient generation of high-quality atomic charges. AM1-BCC model: II. Parameterization and validation. Journal of Computational Chemistry, 2002, 23(16): 1623-1641.

[47] Jorgensen W. L., Chandrasekhar J., Madura J. D., et al. Comparison of simple potential functions for simulating liquid water. Journal of Chemical Physics, 1983, 79(2): 926-935.

[48] Maier J. A., Martinez C., Kasavajhala K., et al. ff14SB: IMcl-1ving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SB. Journal of Chemical Theory and Computation, 2015, 11(8): 3696-3713.

[49] Wang J., Wolf R. M., Caldwell J. W., et al. Development and testing of a general amber force field. Journal of Computational Chemistry, 2004, 25(9): 1157-1174.

[50] Izaguirre J. A., Catarello D. P., Wozniak J. M., et al. Langevin stabilization of molecular dynamics. Journal of Chemical Physics, 2001, 114(5): 2090-2098.

[51] Ryckaert J. P., Ciccotti G., Berendsen H. J. C. Numerical integration of the cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes. Journal of Computational Physics, 1977, 23(3): 327-341.

[52] Darden T., York D., Pedersen L. Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems. Journal of Chemical Physics, 1993, 98(12): 10089-10092.

[53] Essmann U., Perera L., Berkowitz M. L., et al. A smooth particle mesh Ewald method. Journal of Chemical Physics, 1995, 103(19): 8577-8593.

[54] Weiser J., Shenkin P. S., Still W. C. Approximate atomic surfaces from linear combinations of pairwise overlaps (LCPO). Journal of Computational Chemistry, 1999, 20(2): 217-230.

[55] Götz A. W., Williamson M. J., Xu D., et al. Routine Microsecond Molecular Dynamics Simulations with AMBER on GPUs. 1. Generalized Born. Journal of Chemical Theory and Computation, 2012, 8(5): 1542-1555.

[56] Salomon-Ferrer R., Götz A. W., Poole D., et al. Routine Microsecond Molecular Dynamics Simulations with AMBER on GPUs. 2. Explicit Solvent Particle Mesh Ewald. Journal of Chemical Theory and Computation, 2013, 9(9): 3878-3888.

[57] J. Su, X. Liu, S. Zhang, F. Yan, Q. Zhang, and J. Chen, A computational insight into binding modes of inhibitors XD29, XD35, and XD28 to bromodomain-containing protein 4 based on molecular dynamics simulations, J. Biomol. Struct. Dyn. 36 (2018), 1212–1224. 

[58] L. Duan, X. Liu, and J.Z.H. Zhang, Interaction entropy: A new paradigm for highly efficient and reliable computation of protein–ligand binding free energy, J. Am. Chem. Soc. 138 (2016), 5722–5728. 

[59] J. Chen, X. Liu, S. Zhang, J. Chen, H. Sun, L. Zhang, and Q. Zhang, Molecular mechanism with regard to the binding selectivity of inhibitors toward FABP5 and FABP7 explored by multiple short molecular dynamics simulations and free energy analyses, Phys. Chem. Chem. Phys. 22 (2020), 2262–2275. 

[60] F. Yan, X. Liu, S. Zhang, J. Su, Q. Zhang, and J. Chen, Molecular dynamics exploration of selectivity of dual inhibitors 5M7, 65X, and 65Z toward fatty acid binding proteins 4 and 5, Int. J. Mol. Sci. 19 (2018), 2496. 

[61] S. Tian, J. Zeng, X. Liu, J. Chen, J.Z.H. Zhang, and T. Zhu, Understanding the selectivity of inhibitors toward PI4KIIIα and PI4KIIIβ based molecular modeling, Phys. Chem. Chem. Phys. 21 (2019), 22103–22112. 

[62] H. Gohlke, C. Kiel, and D.A. Case, Insights into protein–protein binding by binding free energy calculation and free energy decomposition for the Ras–Raf and Ras–RalGDS complexes, J. Mol. Biol. 330 (2003), 891–913. 

[63] B. Xu, H. Shen, X. Zhu, and G. Li, Fast and accurate computation schemes for evaluating vibrational entropy of proteins, J. Comput. Chem. 32 (2011), 3188–3193.